A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)

NCT ID: NCT01076400

Last Updated: 2023-09-18

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-05-31
• Study Completion Date: 2011-06-13

Brief Summary

This study will be conducted in two parts. Part 1 will determine whether administration of adavosertib in combination with topotecan and cisplatin is generally well-tolerated and causes clinical objective responses in patients with cervical cancer. Part 1 will also define the recommended Phase 2 dose and maximum tolerated dose (MTD) of the combination of adavosertib with topotecan and cisplatin. Part 2 of the study will evaluate whether treatment with adavosertib in combination with topotecan and cisplatin causes an improvement in progression-free survival (PFS) compared to treatment with topotecan and cisplatin alone and will further evaluate the tolerability of the combination treatment. The primary hypothesis is the combination of adavosertib, topotecan and cisplatin causes objective radiological responses (assessed per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) in ≥30% of participants. Due to the early termination of the study by the sponsor, no participants were enrolled in Part 2 of the study.

Conditions

Cervical Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Part 1: adavosertib + topotecan/cisplatin

Part 1: Dose escalation study. adavosertib capsules will be administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3 . Cisplatin will be administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.

Group Type: EXPERIMENTAL

adavosertib

Intervention Type: DRUG

Adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.

Topotecan

Intervention Type: DRUG

Topotecan is administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3.

Cisplatin

Intervention Type: DRUG

Cisplatin is administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.

Part 2: adavosertib + topotecan/cisplatin

Part 2: adavosertib capsules will be administered at the dose determined in Part 1 twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3. Cisplatin will be administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.

Group Type: EXPERIMENTAL

adavosertib

Intervention Type: DRUG

Adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.

Topotecan

Intervention Type: DRUG

Topotecan is administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3.

Cisplatin

Intervention Type: DRUG

Cisplatin is administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.

Part 2: Placebo to adavosertib + topotecan/cisplatin

Part 2: Placebo to adavosertib capsules will be administered twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3. Cisplatin will be administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.

Group Type: PLACEBO_COMPARATOR

Topotecan

Intervention Type: DRUG

Topotecan is administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3.

Cisplatin

Intervention Type: DRUG

Cisplatin is administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.

Placebo to adavosertib

Intervention Type: DRUG

Placebo to adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.

Interventions

adavosertib

Adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.

Intervention Type: DRUG

Topotecan

Topotecan is administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3.

Intervention Type: DRUG

Cisplatin

Cisplatin is administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.

Intervention Type: DRUG

Placebo to adavosertib

Placebo to adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.

Intervention Type: DRUG

Other Intervention Names

MK-1775

Eligibility Criteria

Inclusion Criteria

• Has advanced, metastatic, and recurrent squamous cell, adenosquamous, or adeno-carcinoma of the uterine cervix (Stage II - IVb)
• Has received cisplatin in combination with radiation as initial or adjuvant treatment for their cervical cancer
• Has not received any other treatment for their cancer following the cisplatin-based chemo-radiation or targeted therapy except non-cytotoxic targeted therapy
• Recurrence must be at least 6 months post cisplatin-based chemotherapy
• Has measurable disease
• Performance status on the Eastern Cooperative Oncology Group (ECOG) Performance Scale is less than or equal to 1
• Has a negative pregnancy test within 72 hours of the first dose of study medication

Exclusion Criteria

• Has had chemotherapy, radiotherapy, or biological therapy within 6 months of entering the study
• Has a history of vascular thrombotic events or vascular reconstruction
• Has active central nervous system (CNS) metastases and/or carcinomatous meningitis
• Has a primary CNS tumor
• Requires the use of medications or products that are metabolized by, or inhibit or induce CYP3A4 (Cytochrome P450 3A4)
• Is expecting to reproduce within the duration of the study or is pregnant or breastfeeding
• Is known to be Human Immunodeficiency Virus (HIV)-positive
• Has known active Hepatitis B or C
• Has a known history of interstitial lung disease or pulmonary fibrosis
• Has symptomatic ascites or pleural effusion
• Has a clinical history suggestive of Li-Fraumeni Syndrome

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Related Links

https://www.merckclinicaltrials.com/

Merck Clinical Trial Information

Other Identifiers

MK-1775-008

Identifier Type: OTHER

Identifier Source: secondary_id

2009-017054-12

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1775-008

Identifier Type: -

Identifier Source: org_study_id